220 related articles for article (PubMed ID: 26758283)
1. Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.
Oosting RS; Chan JS; Olivier B; Banerjee P; Choi YK; Tarazi F
Psychopharmacology (Berl); 2016 Mar; 233(6):1025-34. PubMed ID: 26758283
[TBL] [Abstract][Full Text] [Related]
2. Vilazodone does not inhibit sexual behavior in male rats in contrast to paroxetine: A role for 5-HT1A receptors?
Oosting RS; Chan JSW; Olivier B; Banerjee P
Neuropharmacology; 2016 Aug; 107():271-277. PubMed ID: 27040795
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
[TBL] [Abstract][Full Text] [Related]
5. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA; Watson JM
CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
[TBL] [Abstract][Full Text] [Related]
6. Long-term administration of the antidepressant vilazodone modulates rat brain monoaminergic systems.
El Mansari M; Crnic A; Oosterhof C; Blier P
Neuropharmacology; 2015 Dec; 99():696-704. PubMed ID: 26362359
[TBL] [Abstract][Full Text] [Related]
7. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
8. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.
Clayton AH; Gommoll C; Chen D; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Jul; 30(4):216-23. PubMed ID: 26039688
[TBL] [Abstract][Full Text] [Related]
9. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
10. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Sahli ZT; Banerjee P; Tarazi FI
Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
[TBL] [Abstract][Full Text] [Related]
11. 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI).
Hjorth S; Auerbach SB
Behav Brain Res; 1996; 73(1-2):281-3. PubMed ID: 8788519
[TBL] [Abstract][Full Text] [Related]
12. Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release.
Nagayasu K; Yatani Y; Kitaichi M; Kitagawa Y; Shirakawa H; Nakagawa T; Kaneko S
Br J Pharmacol; 2010 Dec; 161(7):1527-41. PubMed ID: 20698856
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid receptor antagonism augments fluoxetine-induced downregulation of the 5-HT transporter.
Johnson DA; Ingram CD; Grant EJ; Craighead M; Gartside SE
Neuropsychopharmacology; 2009 Jan; 34(2):399-409. PubMed ID: 18496518
[TBL] [Abstract][Full Text] [Related]
14. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.
de Jong TR; Pattij T; Veening JG; Waldinger MD; Cools AR; Olivier B
Psychopharmacology (Berl); 2005 May; 179(2):509-15. PubMed ID: 15719219
[TBL] [Abstract][Full Text] [Related]
16. [Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine].
Le Poul E; Lima L; Laporte AM; Even C; Doucet E; Fattaccini CM; Laaris N; Hamon M; Lanfumey L
Encephale; 1995; 21(2):123-32. PubMed ID: 7781583
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.
Ashby CR; Kehne JH; Bartoszyk GD; Renda MJ; Athanasiou M; Pierz KA; Seyfried CA
Eur J Pharmacol; 2013 Aug; 714(1-3):359-65. PubMed ID: 23872377
[TBL] [Abstract][Full Text] [Related]
18. Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors.
Hjorth S; Auerbach SB
Eur J Pharmacol; 1994 Aug; 260(2-3):251-5. PubMed ID: 7988652
[TBL] [Abstract][Full Text] [Related]
19. The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter.
Plenge P; Yang D; Salomon K; Laursen L; Kalenderoglou IE; Newman AH; Gouaux E; Coleman JA; Loland CJ
Nat Commun; 2021 Aug; 12(1):5063. PubMed ID: 34417466
[TBL] [Abstract][Full Text] [Related]
20. Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study.
Clayton AH; Durgam S; Li D; Chen C; Chen L; Mathews M; Gommoll CP; Szegedi A
Int Clin Psychopharmacol; 2017 Jan; 32(1):27-35. PubMed ID: 27643885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
